 IRVING, Texas, and HOUSTON, and VANCOUVER, BC, Oct. 7, 2021 PRNewswire -- Caris Life Sciences, a molecular science company developing and delivering technologies to revolutionize healthcare, and ESSA Pharma Inc. Nasdaq: EPIX ESSA, a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today a Precision Development program to support ESSAs ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer mCRPC failing current standard-of-care therapies. Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris Whole Transcriptome Sequencing WTS and Whole Exome Sequencing WES platform. 